Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I-Net Corp
TSE:9600
|
JP |
|
Qingdao Daneng Environmental Protection Equipment Co Ltd
SSE:688501
|
CN |
|
Shanghai Runda Medical Technology Co Ltd
SSE:603108
|
CN |
|
Technocraft Industries (India) Ltd
NSE:TIIL
|
IN |
|
Nissan Shatai Co Ltd
TSE:7222
|
JP |
|
F
|
Finolex Cables Ltd
BSE:500144
|
IN |
|
Y
|
Yesil Yatirim Holding AS
IST:YESIL.E
|
TR |
Molecular Partners AG
Depreciation & Amortization
Molecular Partners AG
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Depreciation & Amortization
-CHf2.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Depreciation & Amortization
-CHf24.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Depreciation & Amortization
-CHf1.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Depreciation & Amortization
-CHf1.9m
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Depreciation & Amortization?
Depreciation & Amortization
-2.1m
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Depreciation & Amortization amounts to -2.1m CHF.
What is Molecular Partners AG's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
6%
Over the last year, the Depreciation & Amortization growth was 9%. The average annual Depreciation & Amortization growth rates for Molecular Partners AG have been 4% over the past three years , 6% over the past five years .
